Skip to content

Evaluating Control of Hypertension - Effect of Social Determinants

Evaluating Control of Hypertension - Effect of Social Determinants

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03545763
Acronym
ECHOES
Enrollment
1939783
Registered
2018-06-04
Start date
2018-04-01
Completion date
2023-05-15
Last updated
2024-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension, Social Determinants of Health, Health Insurance, Medicaid, Affordable Care Act

Brief summary

This study evaluates the impact of a large-scale, national expansion of Medicaid on hypertension incidence, screening, treatment, and management. Social Determinants of Health will be assessed as moderators, and comparing states that did versus states that did not expand Medicaid will also be evaluated.

Detailed description

The Affordable Care Act (ACA) enacted several provisions intended to improve healthcare for vulnerable populations,including expanding Medicaid eligibility to those earning ≤138% of the federal poverty level (FPL). Since the expansion was not required, as of March 2018, 32 states (and District of Columbia) implemented the expansion and 18 did not. Simulated models predicted the ACA would improve health outcomes and reduce disparities for patients with hypertension, yet actual changes are not yet available. In addition, there is new interest in tracking and utilizing Social Determinants of Health (SDH) in the primary care setting but there is currently little information on how this information will impact Hypertension (HTN) care, especially related to changes to health insurance availability. This study will build on current understanding of how health insurance impacts HTN incidence, screening, treatment, and management by comparing states that did versus did not expand Medicaid as part of the ACA and seeks to understand the influence of SDH on these changes. the investigators will address the following specific aims: Aim 1: Compare HTN incidence, prevalence of undiagnosed HTN, and rates of HTN screening, in Medicaid expansion versus non-expansion states before and after the ACA. Aim 2: Compare HTN treatment (e.g., medication use), and management (e.g., HTN control, systolic and diastolic blood pressure change, risk factors related to HTN control) in Medicaid expansion versus non-expansion states before and after the ACA. Aim 3: Assess the extent to which rates of HTN incidence, screening, and treatment effectiveness among patients who gained insurance versus those continuously insured or uninsured, pre-post ACA, are moderated by individual-level SDH (e.g., race, ethnicity), in expansion states. Aim 4: Explore the interaction between community-level SDH (e.g., neighborhood racial segregation and deprivation) and HTN incidence, screening, treatment, and management among patients who gained insurance relative to those who were continuously insured or uninsured, in expansion states. The findings from this project will be extremely relevant to policy and practice, informing further improvements in the US healthcare system to ensure access to healthcare for vulnerable populations.

Interventions

There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not

Sponsors

OCHIN, Inc.
CollaboratorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Health Choice Network
CollaboratorOTHER
Fenway Community Health
CollaboratorOTHER
Oregon Health and Science University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Patients in intervention and control states aged 19-64

Exclusion criteria

* Patients outside of age range 19-64

Design outcomes

Primary

MeasureTime frameDescription
Hypertension management24 months prior to Medicaid expansion vs 24 months postblood pressure control: last measure within range of normal for age/risk(s); percent Y/N at last visit, value/date of last measure
Hypertension incidence24 months prior to Medicaid expansion vs 24 months postRates of hypertension diagnosis using the following codes in the EHR: ICD-9: 401.00-401.99, 402.00-405.99 or ICD-10: I10-I15.
Undiagnosed hypertension24 months prior to Medicaid expansion vs 24 months posthigh blood pressure but no diagnosis or medications can be noted in the EHR diagnostic codes that can be used to document why a diagnosis of hypertension was not made including ICD-10 R03.0 (i.e., white coat syndrome without HTN) and ICD-9 796.2 (i.e., elevated BP without HTN).
Hypertension screening24 months prior to Medicaid expansion vs 24 months postrate of blood pressure screening marked in EHR
Hypertension treatment24 months prior to Medicaid expansion vs 24 months postthe number of anti-hypertensive medications prescribed in EHR

Secondary

MeasureTime frameDescription
Service Utilization24 months prior to Medicaid expansion vs 24 months postType of internal services utilized including number and ratio of traditional face to face visits vs. nontraditional encounters and communication via phone, personal health record, and email
Preventive service receipt24 months prior to Medicaid expansion vs 24 months postnumber of all billed encounters overall and yearly, as well as number of cancer screening, smoking screening, lipid screening, diabetes screening, obesity screening
Hypertension related complications24 months prior to Medicaid expansion vs 24 months postincidence of related complications and diseases derived from EHR data
Insurance status and rates of coverage24 months prior to Medicaid expansion vs 24 months postHealth insurance status derived from EHR data and is primarily based on information collected at each visit

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026